In a fast paced world, AbbVie Inc (NYSE:ABBV) intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late stage cancer drug of the company as a strong reason due to which it wanted to acquire Imbruvica-maker Pharmacyclics for a whopping $21 billion.
AbbVie anticipates that if blood cancer blockbuster is matched with its experimental therapy, it can easily elevate its market share and reach in the domestic and international market. Reports claim that FDA has taken this argument to all new heights with BTD or breakthrough therapy designation for venetoclax. Experts claim that the procedure of getting approval for this therapy will now become easy and hassle-free for the company.
Road So Far:
Initially, the U.S. Food and Drug Administration handed out the bragging rights of breakthrough therapy designation for patients that have chronic lymphocytic leukemia (CLL) and suffering from 17p deletion genetic mutation. Close to 3%-10% of all the first line patients suffer from this type of mutation.
ASH which has partnered with Roche impressed analysts in 2014 with its extra-ordinary results. During the procedure, investigators found an 88% response rate and a wide number of remissions among refractory CLL patients who took Rituxan and venetocla together.
Venetoclax works excellent by inhibiting the protein named BCL-2, which is responsible for saving cells from dying. It makes venetoclax a natural therapy to treat such deadly disease at a time when scientists are trying to figure out optimal solutions in a cost effective way.
Drug makers have started focusing on enhancing their investments in oncology. It’s an ideal opportunity for venetoclax to hit the market and take the standards to a new level. AbbVie Inc (NYSE:ABBV) takes it as a great opportunity and hopes that it will be able to come up with an effective solution for cancer in the near future.
